Clinical Trial Update: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating consolidation with loncastuximab tesirine after a short course of immunochemotherapy in BTKi-treated or intolerant relapsed/refractory …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Zynlonta (loncastuximab tesirine)

Snippet

Sponsor: Fondazione Italiana Linfomi - ETS | Conditions: Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 2 | Status: RECRUITING